UBS Group Boosts Elanco Animal Health (NYSE:ELAN) Price Target to $33.00

Elanco Animal Health (NYSE:ELAN) had its target price boosted by equities research analysts at UBS Group from $31.00 to $33.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. UBS Group’s target price points to a potential upside of 34.78% from the company’s current price.

Other research analysts also recently issued research reports about the company. Morgan Stanley lifted their price objective on Elanco Animal Health from $23.00 to $26.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 22nd. Piper Sandler restated an “overweight” rating on shares of Elanco Animal Health in a research report on Monday, June 29th. Citigroup boosted their price objective on Elanco Animal Health from $30.00 to $31.00 and gave the company a “buy” rating in a research report on Thursday, May 7th. JPMorgan Chase & Co. increased their price objective on Elanco Animal Health from $28.00 to $30.00 and gave the company an “overweight” rating in a research note on Thursday, May 7th. Finally, KeyCorp boosted their price target on Elanco Animal Health from $29.00 to $30.00 and gave the company an “overweight” rating in a report on Thursday. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $29.09.

Elanco Animal Health Price Performance

ELAN stock traded down $1.74 during mid-day trading on Thursday, hitting $24.48. 12,428,110 shares of the stock were exchanged, compared to its average volume of 5,442,954. The business has a fifty day moving average price of $24.73 and a 200 day moving average price of $24.10. Elanco Animal Health has a 12 month low of $15.50 and a 12 month high of $27.98. The company has a debt-to-equity ratio of 0.60, a current ratio of 2.16 and a quick ratio of 1.12. The stock has a market capitalization of $12.23 billion, a price-to-earnings ratio of -48.89, a PEG ratio of 1.67 and a beta of 1.67.

Elanco Animal Health (NYSE:ELAN) last issued its earnings results on Wednesday, August 5th. The company reported $0.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.27 by $0.07. The business had revenue of $1.37 billion during the quarter, compared to analyst estimates of $1.31 billion. Elanco Animal Health had a positive return on equity of 7.42% and a negative net margin of 4.95%.Elanco Animal Health’s revenue for the quarter was up 10.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.26 earnings per share. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. On average, sell-side analysts anticipate that Elanco Animal Health will post 1.11 EPS for the current year.

Insider Buying and Selling

In other news, insider Rajeev A. Modi acquired 4,911 shares of Elanco Animal Health stock in a transaction that occurred on Friday, May 15th. The stock was bought at an average price of $20.35 per share, for a total transaction of $99,938.85. Following the completion of the transaction, the insider owned 160,812 shares in the company, valued at $3,272,524.20. The trade was a 3.15% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Jeffrey N. Simmons acquired 4,971 shares of Elanco Animal Health stock in a transaction dated Friday, May 15th. The stock was bought at an average price of $20.09 per share, with a total value of $99,867.39. Following the completion of the purchase, the chief executive officer directly owned 171,971 shares in the company, valued at $3,454,897.39. This represents a 2.98% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders own 1.14% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in ELAN. T. Rowe Price Investment Management Inc. boosted its stake in shares of Elanco Animal Health by 11.8% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 35,227,418 shares of the company’s stock valued at $797,197,000 after purchasing an additional 3,717,404 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in Elanco Animal Health by 1.5% in the fourth quarter. Dimensional Fund Advisors LP now owns 25,082,545 shares of the company’s stock worth $567,622,000 after buying an additional 373,869 shares in the last quarter. UBS Group AG raised its stake in Elanco Animal Health by 56.7% in the third quarter. UBS Group AG now owns 16,468,148 shares of the company’s stock worth $331,669,000 after buying an additional 5,961,457 shares in the last quarter. Geode Capital Management LLC lifted its holdings in Elanco Animal Health by 7.3% during the fourth quarter. Geode Capital Management LLC now owns 9,425,533 shares of the company’s stock worth $213,343,000 after buying an additional 640,098 shares during the period. Finally, Fuller & Thaler Asset Management Inc. lifted its holdings in Elanco Animal Health by 16.1% during the fourth quarter. Fuller & Thaler Asset Management Inc. now owns 5,771,622 shares of the company’s stock worth $130,612,000 after buying an additional 799,745 shares during the period. 97.48% of the stock is currently owned by institutional investors.

Key Elanco Animal Health News

Here are the key news stories impacting Elanco Animal Health this week:

• Positive Sentiment: Elanco reported second-quarter adjusted EPS of $0.34, above the $0.27 consensus estimate, while revenue rose 10.2% year over year to $1.368 billion, exceeding expectations of $1.31 billion. Elanco Animal Health Reports Second Quarter 2026 Results
• Positive Sentiment: Management raised full-year 2026 adjusted EPS guidance to $1.10-$1.16 from its prior outlook, increased revenue guidance to $5.09-$5.14 billion, lifted adjusted EBITDA guidance to $1.01-$1.035 billion, and raised its innovation-revenue target to $1.25 billion. Zenrelia reportedly reached blockbuster status. Elanco posts Q2 beat as Zenrelia hits blockbuster status
• Positive Sentiment: KeyCorp raised its price target for ELAN to $30 from $29 and maintained an “overweight” rating, indicating continued analyst confidence in the company’s growth outlook. KeyCorp price target update
• Neutral Sentiment: Third-quarter guidance calls for adjusted EPS of $0.19-$0.22 and revenue of approximately $1.2 billion, broadly in line with consensus. That limited near-term upside may be contributing to the weaker stock reaction.
• Negative Sentiment: Although adjusted results were strong, reported net income was $54 million and reported EPS was $0.11. Elanco also remains leveraged at 3.1 times adjusted EBITDA, so investors may remain cautious about debt reduction and the company’s negative GAAP net margin.
• Neutral Sentiment: A Zacks comparison with Addus HomeCare focuses on relative valuation rather than a new company-specific catalyst, potentially prompting investors to reassess whether ELAN’s recent gains adequately reflect its improved outlook. ADUS vs. ELAN: Which Stock Is the Better Value Option?

Elanco Animal Health Company Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.